Skip to Main content Skip to Navigation
Journal articles

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Abstract : Background: Targeted lung denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung reducing clinical consequences of cholinergic hyperactivity. The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe, symptomatic COPD. This analysis evaluated the long-term impact of TLD on COPD exacerbations, pulmonary function, and quality of life over 3 years of follow up. Methods: TLD was performed in a prospective, energy-level randomized (29 W vs 32 W power), multicenter study (NCT02058459). Additional patients were enrolled in an open label confirmation phase to confirm improved gastrointestinal safety after procedural modifications. Durability of TLD was evaluated at 1, 2, and 3 years post-treatment and assessed through analysis of COPD exacerbations, pulmonary lung function, and quality of life. Results: Three-year follow-up data were available for 73.9% of patients (n = 34). The annualized rate of moderate to severe COPD exacerbations remained stable over the duration of the study. Lung function (FEV 1 , FVC, RV, and TLC) and quality of life (SGRQ-C and CAT) remained stable over 3 years of follow-up. No new gastrointestinal adverse events and no unexpected serious adverse events were observed. Conclusion: TLD in COPD patients demonstrated a positive safety profile out to 3 years, with no late-onset serious adverse events related to denervation therapy. Clinical stability in lung function, quality of life, and exacerbations were observed in TLD treated patients over 3 years of follow up.
Complete list of metadata

https://hal.univ-reims.fr/hal-03170571
Contributor : Valerian Dormoy <>
Submitted on : Tuesday, March 16, 2021 - 12:00:53 PM
Last modification on : Monday, May 17, 2021 - 2:52:24 PM
Long-term archiving on: : Thursday, June 17, 2021 - 7:25:14 PM

File

ChristophePison_RespirRes_2021...
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Christophe Pison, Pallav L. Shah, Dirk-Jan Slebos, Vincent Ninane, Wim Janssens, et al.. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. Respiratory Research, BioMed Central, 2021, 22, pp.62. ⟨10.1186/s12931-021-01664-5⟩. ⟨hal-03170571⟩

Share

Metrics

Record views

100

Files downloads

142